Document is current

Article History

Received: 5 July 2024

Accepted: 1 September 2024

First Online: 15 September 2024

Declarations

:

: As described earlier, the human biopsy procedure including the cell culture protocol was approved by the local committee on Research Involving Human Subjects (METC Oost-Nederland; Commissie Mensgebonden Onderzoek (CMO) 2016–2451, NL57509.091.16), entitled “Development of an autologous myogenic cell therapy against the neuromuscular phenotype of myotonic dystrophy type 1”, approval date 18th of October 2016 []. Informed consent to participate in our study was obtained from all participants. No adverse events following the biopsy procedure were reported.

: All authors confirm their consent for publication.

: Several authors of this publication are members of the Radboudumc Center of Expertise for neuromuscular disorders (Radboud-NMD), Netherlands Neuromuscular Center (NL-NMD) and the European Reference Network for rare neuromuscular diseases (EURO-NMD). Within the last 36 months, D.G.W. has been a scientific consultant and/or received an honoraria/grants from Design Therapeutics and Synaffix. Within the last 36 months D.G.M. has been a scientific consultant and/or received an honoraria/grants from AMO Pharma, Dyne, F. Hoffman-La Roche, LoQus23, MOMA Therapeutics, Novartis, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Rgenta Therapeutics, Sanofi, Sarepta Therapeutics Inc, Script Biosciences, Triplet Therapeutics, and Vertex Pharmaceuticals. D.G.M. also had/has research contracts with AMO Pharma and Vertex Pharmaceuticals. B.G.M.v.E. reports grants from or contracts with Prinses Beatrix Spierfonds, the Dutch FSHD Foundation, and Stichting Spieren voor Spieren, royalties and licenses from patent EP2012740236, and institutional payments for consulting and participation on data safety monitoring and advisory boards from Fulcrum Therapeutics, Facio, Avidity, Dyne, Arrowhead, Biomarin, Pepgen, and Teva.